<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346918</article-id>
      <article-id pub-id-type="pmc">3875991</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132588</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Systemic sarcoidosis induced by etanercept: first Brazilian case
report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Sarcoidose sist&#xEA;mica induzida por etanercepte: primeiro relato de caso
brasileiro</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Unterstell</surname>
            <given-names>Natasha</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bressan</surname>
            <given-names>Aline Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Serpa</surname>
            <given-names>Laura Ara&#xFA;jo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Castro</surname>
            <given-names>P&#xE9;rola Peres da Fonseca e</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gripp</surname>
            <given-names>Alexandre Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, resident on the Dermatology Program at Pedro Ernesto University
Hospital- Rio de Janeiro State University (HUPE-UERJ) - Rio de Janeiro (RJ), Brazil .</aff>
      <aff id="aff02"><label>2</label> MD, dermatologist - Attendant at the dermatology ward and the
immunotherapy clinic at Pedro Ernesto University Hospital- Rio de Janeiro State
University (HUPE-UERJ) - Rio de Janeiro(RJ), Brazil .</aff>
      <aff id="aff03"><label>3</label> MD, MSc in dermatology - Chief of the dermatology ward and
immunotherapy clinic at Pedro Ernesto University Hospital- Rio de Janeiro State
University (HUPE-UERJ) - Rio de Janeiro (RJ), Brazil .</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Natasha Unterstell, Av. Vinte e oito de setembro, 70 -
Vila Isabel. 20551-030 - Rio de Janeiro - RJ, Brazil. E-mail:
<email>natasha_unterstell@yahoo.com.br </email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>197</fpage>
      <lpage>199</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>3</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The antagonists of tumor necrosis factor alpha (TNF-&#x3B1;) are increasingly being used in
the treatment of inflammatory and autoimmune diseases. Several adverse effects of
these drugs have been reported, including the paradoxical development of sarcoidosis,
especially with the use of etanercept. We present the first Brazilian case report of
systemic sarcoidosis induced by etanercept and a literature review.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Os medicamentos antagonistas do fator de necrose tumoral alfa (TNF-&#x3B1;) est&#xE3;o sendo
cada vez mais utilizados no tratamento de doen&#xE7;as inflamat&#xF3;rias e autoimunes. Efeitos
adversos desses medicamentos vem sendo relatados, incluindo o desenvolvimento
paradoxal de sarcoidose, principalmente com o uso do etanercepte. Apresentamos o
primeiro relato de caso brasileiro de sarcoidose sist&#xEA;mica induzida por etanercepte e
uma revis&#xE3;o da literatura.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Diagnosis</kwd>
        <kwd>Granuloma</kwd>
        <kwd>Sarcoidosis</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>BACKGROUND</title>
      <p>Sarcoidosis is a multisystem disease of unknown etiology, characterized by the formation
noncaseating granulomas, especially in the lungs, lymphnodes, eyes and skin. <sup><xref ref-type="bibr" rid="r01">1</xref></sup> Tumor necrosis factor antagonists
(anti-TNF) may be used as treatment, however some cases of sarcoidosis secondary to
these same drugs have been detected.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r08">8</xref></sup> We report the case of a female patient,
with rheumatoid arthritis present ing with systemic sarcoidosis after 6 months of treat
ment with etanercept.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A fifty year-old female patient, Caucasian, born in Rio de Janeiro, was diagnosed with
rheumatoid arthritis 10 years ago. She started treatment with weekly etanercept 50 mg
subcutaneously over one year ago, due to a poor therapeutic response to methotrexate,
sulphasalazine and corticoids. Prior to starting the immunobiologic therapy, the patient
was screened with thoracic radiographies, PPD and HIV and hepatitis serologic tests, all
with normal results.</p>
      <p>After 6 months of treatment with etanercept, infiltrated erythematous lesions appeared
surrounding a scar on the posterior region of the right thigh and right gluteal area,
followed by the emergence of painful erythematous nodules on lower limbs and an increase
of volume on the neck (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). Our patient denied fever, weight loss and
dyspnea. At this point, thoracic and cervical computerized tomography scans were
performed, showing pulmonary perihilar lymphadenomegaly and bilateral augmentation of
parotids without lymphadenomegaly, respectively (<xref ref-type="fig" rid="f03">Figure
3</xref>). Histopathological examination of the right thigh skin lesion demonstrated
the presence of noncaseating granulomas formed by histiocytes and giant cells in the
dermis and hypodermis (<xref ref-type="fig" rid="f04">Figures 4</xref> and <xref ref-type="fig" rid="f05">5</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Erythematous, infiltrated lesions surrounding a cicatricial area on the posterior
region of the right thigh</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0197-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Erythema nodosum on lower limbs</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0197-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Thoracic CT scan showing perihilar pulmonary lymphadenomegaly</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0197-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Histopathological exam (100x zoom) of the right thigh lesion showing
well-delimitated, noncaseating granulomas in the dermis and hypodermis</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0197-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Histopathological exam (1000x zoom): noncaseating granuloma formed by histiocytes
and giant cells</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0197-g05"/>
      </fig>
      <p>Skin cultures for mycobacteria and fungi were negative and angiotensin converting enzyme
levels were 61 U/L (reference value: &lt; 60 U/L). </p>
      <p>Etanercept was suspended after the diagnosis of sarcoidosis, and treatment with
prednisone 30mg/day p.o. was initiated resulting in an improvement of skin, cervical and
pulmonary lesions within approximately 30 days. </p>
      <p>The dose of prednisone was gradually reduced after 3 months, and no relapse of symptoms
was observed after 6 months of follow-up. </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The exact etiology of sarcoidosis remains unknown. It is believed that an exacerbated
immune response may occur due to antigenic stimuli such as infectious and environmental
agents and also autoantigens.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>Recent studies demonstrated that TNF-&#x3B1; has a crucial role in forming the inflammatory
granuloma, as well as in regulating adhesion molecules, recruiting cells and activating
lymphocytes.<sup><xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>The formation of the granuloma requires a cellular type (Th1) response pattern;
involving macrophages and T CD4 activated lymphocytes. Interleukin-1b and
gamma-interferon are important promoters during the initial phases of the granuloma
development; TNF-&#x3B1; on the other hand, is critical during the latter phases of the
granulomatous process.<sup><xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Tumor necrosis factor antagonists (anti-TNF) are used to treat sarcoidosis since; in
theory, they would block this cytokine's action.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> However, paradoxically, some cases of sarcoidosis induced by these
same medications have been reported.<sup><xref ref-type="bibr" rid="r08">8</xref></sup>
This perplexing mechanism is not yet clear, but it is believed that these drugs do not
inhibit all the signaling pathways of TNF-&#x3B1;, thus ensuing some "escape"
routes.<sup><xref ref-type="bibr" rid="r02">2</xref>-<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>In a review published on May 2012, (Cathcart, <italic>et al</italic>
<sup><xref ref-type="bibr" rid="r06">6</xref></sup>), 34 cases of sarcoidosis induced by
TNF-&#x3B1; antagonists had already been described on the medical literature. Twenty-one of
those (61.7%) occurred after the use of etanercept, 9 (26.4%) after infliximab and 4
(11.7%) after adalimumab. In this study, the mean time for the appearance of granulomas
was 22 months after the start of medications.<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>After a literature review, we found 48 case reports of sarcoidosis induced by TNF- &#x3B1;
antagonists. Thirty- one (64.58%) followed etanercept, 9 (18.75%) occurred after
infliximab and 8 (16.66%) after adalimumab. Most patients had pulmonary and/or lymphnode
involvement, with 8 cases of cutaneous manifestations, mainly of erythema
nodosum.<sup><xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Despite all the anti-TNF drugs having the ability to block pro-inflammatory cytokine
TNF-&#x3B1;, they possess marked differences in their own structures, as well as their
pharmacokinetics and pharmacodynamics' attributes, which explains, in part, the
diversity that may be observed in clinical efficacy and adverse events, including the
triggering of granulomatous lesions.<sup><xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>The inhibition of TNF-&#x3B1; by etanercept is not a complete one, since this drug connects
only to the soluble TNF receptor and not to the transmembrane receptor, as occurs with
infliximab and adalimumab. Partial neutralization of TNF-&#x3B1; by etanercept permits the
redistribution of this cytokine in areas of lower concentration, such as the lungs. This
may explain the stronger association of granulomatous reactions with the use of
etanercept.<sup><xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>The treatment of such cases has been the suspension of the anti-TNF agent and in some
cases, as reported here, the introduction of corticoids. The mean time to recovery of
symptoms after the interruption of the drug is 5.2 months.<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>Considering that these drugs are increasingly used in dermatology, we must remain alert
to the possibility of sarcoidosis, especially if respiratory symptoms, or erythema
nodosum and/or granulomatous cutaneous eruptions arise.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at Pedro Ernesto University Hospital- Rio de Janeiro State University
(HUPE-UERJ) - Rio de Janeiro (RJ), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daldon</surname>
              <given-names>PEC</given-names>
            </name>
            <name>
              <surname>Arruda</surname>
              <given-names>LHF</given-names>
            </name>
          </person-group>
          <article-title>Noninfectious granulomas: sarcoidosis</article-title>
          <source>An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>559</fpage>
          <lpage>571</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aguiar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mar&#xE7;al</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mendes</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bugalho de Almeida</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Infliximab for treating sarcoidosis patients, Portuguese
experience</article-title>
          <source>Rev Port Pneumol</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>85</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">21477572</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hostettler</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Studler</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Tamm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brutsche</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Long-term treatment with infliximab in patients with
sarcoidosis</article-title>
          <source>Respiration</source>
          <year>2012</year>
          <volume>83</volume>
          <fpage>218</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">21811048</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gifre</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ruiz-Esquide</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Xaubet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>G&#xF3;mez-Puerta</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hern&#xE1;ndez</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Sanmart&#xED;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a
case presentation and a literature review</article-title>
          <source>Arch Bronconeumol</source>
          <year>2011</year>
          <volume>47</volume>
          <fpage>208</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">20638761</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fok</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Connor</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous sarcoidosis in a patient with ulcerative colitis on
infliximab</article-title>
          <source>J Crohns Colitis</source>
          <year>2012</year>
          <volume>6</volume>
          <fpage>708</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="pmid">22398084</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cathcart</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sami</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Elewski</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Sarcoidosis as an adverse effect of tumor necrosis factor
inhibitors</article-title>
          <source>J Drugs Dermatol</source>
          <year>2012</year>
          <volume>11</volume>
          <fpage>609</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="pmid">22527429</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamrock</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Development of cutaneous sarcoidosis during treatment with tumor
necrosis alpha factor antagonists</article-title>
          <source>Australas J Dermatol</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>e87</fpage>
          <lpage>e90</lpage>
          <pub-id pub-id-type="pmid">23157794</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Massara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavazzini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>La Corte</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Trotta</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy:
a new 'class effect' paradoxical phenomenon. Two case reports and literature
review</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2010</year>
          <volume>39</volume>
          <fpage>313</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="pmid">19147181</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lukacs</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Chensue</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Warmington</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory granuloma formation is mediated by TNF-alpha-inducible
intercellular adhesion molecule-1</article-title>
          <source>J Immunol</source>
          <year>1994</year>
          <volume>152</volume>
          <fpage>5883</fpage>
          <lpage>5889</lpage>
          <pub-id pub-id-type="pmid">7911491</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vigne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tebib</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Pacheco</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Coury</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Sarcoidosis: An underestimated and potentially severe side effect of
anti-TNF-alpha therapy</article-title>
          <source>Joint Bone Spine</source>
          <year>2013</year>
          <volume>80</volume>
          <fpage>104</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="pmid">22885144</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
